ANIP 55.46 ANI Pharmaceuticals Inc $ANIP Hit a 52 week high of 55.88 Closing the day 09:44 at 55.46 -0.20 -0.36% With a day low of 54.74 and a total volume of 16,557.
ANIP Recent Posts: http://investorshangout.com/ANI-Pharmaceutica...NIP-53540/
ANIP ANI Pharmaceuticals Inc Recent Headline News
Amarin Corporation plc (AMRN) in Focus: Stock Soars 23.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 3 mins ago
Amarin Corporation plc (AMRN) was a big mover last session, as the company saw its shares rise by over 23% on the day.
ANIP: 55.07 (-0.59), AMRN: 1.33 (+0.01), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49)
Kite Pharma Gains on Positive Opinion for KTE-C19 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:30PM CST
Kite Pharma (KITE) received a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products for granting orphan medicinal product status to KTE-C19.
BIIB: 303.77 (-1.79), KITE: 44.04 (+2.27), ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47)
Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:21AM CST
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49), FOLD: 6.89 (+0.14)
Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - Tue Nov 18, 8:18AM CST
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 55.07 (-0.59), CLDX: 18.50 (+0.78), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49)
Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 2:30PM CST
The latest Interbody and orthobiologic device launches are expected to drive a sequential increase in Integra Lifesciences' (IART) spine sales in the fourth quarter of 2014.
IART: 47.27 (-0.22), ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49)
Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:42AM CST
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 303.77 (-1.79), KITE: 44.04 (+2.27), ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47)
Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:45AM CST
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49), PBYI: 222.26 (-0.74)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 303.77 (-1.79), ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49)
Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 55.07 (-0.59), ICPT: 158.82 (-3.68), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49)
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:26AM CST
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue?
ANIP: 55.07 (-0.59)
ANI Pharma (ANIP) & Sucampo Pharma (SCMP): Top Momentum Stocks to Add to Your Portfolio - Video Blog
David Bartosiak - Zacks Investment Research - Wed Nov 12, 1:59PM CST
ANI Pharma (ANIP) & Sucampo Pharma (SCMP), this week's top momentum stocks are discussed by Momentum Strategist David Bartosiak.
ANIP: 55.07 (-0.59), SCMP: 11.67 (-0.38)
Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:54AM CST
ANI Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ANIP: 55.07 (-0.59)
Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 303.73 (-1.83), ANIP: 55.07 (-0.59), CLDX: 18.50 (+0.78), AMAG: 34.87 (-0.47)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ALLY: 23.40 (-0.21), ANIP: 55.07 (-0.59), ACGL: 56.76 (-0.20), ACCO: 8.90 (+0.01), FLWS: 8.59 (-0.06)
ANI Pharmaceuticals Announces the Launch of Methazolamide Tablets USP
PR Newswire - Thu Nov 06, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced the launch of Methazolamide USP 25mg and 50mg oral tablets, indicated for the treatment of ocular conditions. The US market for Methazolamide totals $24 million on a trailing 12 month basis, per IMS Health.
ANIP: 55.07 (-0.59)
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
SYKE: 23.00 (-0.26), HBNK: 19.88 (-0.45), ASMI: 42.02 (+0.31), RRGB: 66.62 (-0.61), SAPE: 24.66 (+0.01), PLUG: 4.10 (+0.06), ANIP: 55.07 (-0.59), ODP: 6.65 (-0.04), MTEX: 22.33 (+0.66), JAXB: 12.24 (+1.19), ALQA: 4.94 (-0.06), YRCW: 22.10 (-0.62)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 6.38 (-0.12), NEO: 4.57 (-0.04), AU: 9.96 (-0.31), FNHC: 25.34 (+0.89), AMS: 2.53 (unch), NYMX: 0.50 (unch), AMDA: 1.32 (+0.06), CVD: 100.88 (+0.08), GBIM: 6.90 (+0.03), RCAP: 12.54 (-0.42), KBIO: 1.93 (-0.04), COOL: 0.70 (-0.02), SAPE: 24.66 (+0.01), XTLB: 2.45 (-0.13), GERN: 3.16 (-0.01), ANIP: 55.07 (-0.59), BBLU: 1.17 (-0.02), NXTD: 2.24 (+0.02), AP: 17.80 (-0.59), ALQA: 4.94 (-0.06)
ANI Pharma ups revenues 123% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:21AM CST
ANIP: 55.07 (-0.59)
ANI posts 3Q profit
Automated Insights - Mon Nov 03, 7:46AM CST
BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Monday reported profit of $6.7 million in its third quarter.
ANIP: 55.07 (-0.59)
ANI Pharmaceuticals beats by $0.20, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 7:34AM CST
ANIP: 55.07 (-0.59)
ANIP Recent Posts: http://investorshangout.com/ANI-Pharmaceutica...NIP-53540/
ANIP ANI Pharmaceuticals Inc Recent Headline News
Amarin Corporation plc (AMRN) in Focus: Stock Soars 23.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 3 mins ago
Amarin Corporation plc (AMRN) was a big mover last session, as the company saw its shares rise by over 23% on the day.
ANIP: 55.07 (-0.59), AMRN: 1.33 (+0.01), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49)
Kite Pharma Gains on Positive Opinion for KTE-C19 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:30PM CST
Kite Pharma (KITE) received a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products for granting orphan medicinal product status to KTE-C19.
BIIB: 303.77 (-1.79), KITE: 44.04 (+2.27), ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47)
Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:21AM CST
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49), FOLD: 6.89 (+0.14)
Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - Tue Nov 18, 8:18AM CST
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 55.07 (-0.59), CLDX: 18.50 (+0.78), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49)
Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 2:30PM CST
The latest Interbody and orthobiologic device launches are expected to drive a sequential increase in Integra Lifesciences' (IART) spine sales in the fourth quarter of 2014.
IART: 47.27 (-0.22), ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49)
Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:42AM CST
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 303.77 (-1.79), KITE: 44.04 (+2.27), ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47)
Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:45AM CST
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49), PBYI: 222.26 (-0.74)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 303.77 (-1.79), ANIP: 55.07 (-0.59), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49)
Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 55.07 (-0.59), ICPT: 158.82 (-3.68), AMAG: 34.87 (-0.47), AFFX: 9.09 (-0.49)
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:26AM CST
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue?
ANIP: 55.07 (-0.59)
ANI Pharma (ANIP) & Sucampo Pharma (SCMP): Top Momentum Stocks to Add to Your Portfolio - Video Blog
David Bartosiak - Zacks Investment Research - Wed Nov 12, 1:59PM CST
ANI Pharma (ANIP) & Sucampo Pharma (SCMP), this week's top momentum stocks are discussed by Momentum Strategist David Bartosiak.
ANIP: 55.07 (-0.59), SCMP: 11.67 (-0.38)
Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:54AM CST
ANI Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ANIP: 55.07 (-0.59)
Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 303.73 (-1.83), ANIP: 55.07 (-0.59), CLDX: 18.50 (+0.78), AMAG: 34.87 (-0.47)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ALLY: 23.40 (-0.21), ANIP: 55.07 (-0.59), ACGL: 56.76 (-0.20), ACCO: 8.90 (+0.01), FLWS: 8.59 (-0.06)
ANI Pharmaceuticals Announces the Launch of Methazolamide Tablets USP
PR Newswire - Thu Nov 06, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced the launch of Methazolamide USP 25mg and 50mg oral tablets, indicated for the treatment of ocular conditions. The US market for Methazolamide totals $24 million on a trailing 12 month basis, per IMS Health. ANIP: 55.07 (-0.59)
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
SYKE: 23.00 (-0.26), HBNK: 19.88 (-0.45), ASMI: 42.02 (+0.31), RRGB: 66.62 (-0.61), SAPE: 24.66 (+0.01), PLUG: 4.10 (+0.06), ANIP: 55.07 (-0.59), ODP: 6.65 (-0.04), MTEX: 22.33 (+0.66), JAXB: 12.24 (+1.19), ALQA: 4.94 (-0.06), YRCW: 22.10 (-0.62)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 6.38 (-0.12), NEO: 4.57 (-0.04), AU: 9.96 (-0.31), FNHC: 25.34 (+0.89), AMS: 2.53 (unch), NYMX: 0.50 (unch), AMDA: 1.32 (+0.06), CVD: 100.88 (+0.08), GBIM: 6.90 (+0.03), RCAP: 12.54 (-0.42), KBIO: 1.93 (-0.04), COOL: 0.70 (-0.02), SAPE: 24.66 (+0.01), XTLB: 2.45 (-0.13), GERN: 3.16 (-0.01), ANIP: 55.07 (-0.59), BBLU: 1.17 (-0.02), NXTD: 2.24 (+0.02), AP: 17.80 (-0.59), ALQA: 4.94 (-0.06)
ANI Pharma ups revenues 123% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:21AM CST
ANIP: 55.07 (-0.59)
ANI posts 3Q profit
Automated Insights - Mon Nov 03, 7:46AM CST
BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Monday reported profit of $6.7 million in its third quarter.
ANIP: 55.07 (-0.59)
ANI Pharmaceuticals beats by $0.20, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 7:34AM CST
ANIP: 55.07 (-0.59)
